EASL recommendations on treatment of hepatitis C: Final update of the series☆
- PMID: 32956768
- DOI: 10.1016/j.jhep.2020.08.018
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Erratum in
-
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series' [J Hepatol 73 (2020) 1170-1218].J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1. J Hepatol. 2023. PMID: 36464532 No abstract available.
Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest Jean-Michel Pawlotsky: Grant and research support: Abbott, Vela Diagnostics. Advisory Boards: Abbvie, Arbutus, Gilead, GlaxoSmithKline, Merck, Regulus and Siemens Healthcare. Speaking and teaching: Abbvie and Gilead. Alessio Aghemo: Grant and research support: Abbvie and Gilead. Advisory Boards: Abbvie, Alfasigma, Gilead, Intercept, Merck and Mylan. Speaking and teaching: Abbvie, Alfasigma, Gilead, Intercept, Merck and Mylan. Marina Berenguer: Grant and research support: Gilead. Advisory Boards: Abbvie, Gilead and Intercept. Speaking and teaching: Abbvie, Astellas, Intercept and Novartis. Olav Dalgard: Grant and research support: Abbvie, Gilead and Merck. Advisory Boards: Gilead and Merck. Speaking and teaching: Abbvie and Merck. Geoffrey Dusheiko: Grant and research support: Abbott, Cepheid, Gilead and Merck. Advisory Boards: Abbott, Arbutus, Gilead. Safety monitoring boards: Enanta and Janssen. Speaking and teaching: Cepheid and Gilead. Fiona Marra: Grant and research support: Abbvie and Gilead. Advisory Boards: Abbvie, Gilead, Merck and Viiv. Speaking and teaching: Abbvie, Gilead and Merck. Francesco Negro: Grant and research support: Abbvie and Gilead. Advisory Boards: Abbvie, Gilead and Merck. Speaking and teaching: Abbvie and Gilead. Massimo Puoti: Grant and research support: Cepheid, Gilead, Merck and Viiv. Advisory Boards: Abbvie, Bristol-Myers Squibb, Gilead, Merck and Viiv. Speaking and teaching: Abbvie, Beckman-Coulter, Bristol-Myers Squibb, Correvio, Gilead, Janssen, Merck, Nordic Pharma, Pfizer, Roche, Roche Diagnostics and Viiv. Heiner Wedemeyer: Grant and research support: Abbott, Abbvie, Bristol-Myers Squibb, Gilead, Novartis and Roche Diagnostics. Advisory Boards: Abbott, Abbvie, Bayer, Bristol-Myers Squibb, Eiger, Gilead, Intercept, Janssen, Merck, Myr GmbH, Novartis and Roche Diagnostics. Speaking and teaching: Abbott, Abbvie, Bristol-Myers Squibb, Falk Foundation, Gilead, Novartis, Roche Diagnostics and Siemens. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues.J Hepatol. 2021 Feb;74(2):473-474. doi: 10.1016/j.jhep.2020.10.013. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33223214 No abstract available.
-
Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".J Hepatol. 2021 Feb;74(2):474-475. doi: 10.1016/j.jhep.2020.10.025. Epub 2020 Nov 20. J Hepatol. 2021. PMID: 33229012 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical